Eli Lilly and Company (LLY) — closed signal from May 13, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 11, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$960.00 – $1,010.00Entry zone — fair-value band
$1,006.87Published — price the day we called it
$1,127.69Target — the price the thesis aimed for
$1,249.45Peak — highest point inside the window, not a realized return
$1,215.02Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 15 days.
Peak price
$1,249.45
peak on July 7, 2026 — not a realized returnPeak gain
+24.1%
peak, from the publication priceWindow close
$1,215.02
end-of-window price, context onlyDays to target
15
Window
May 13, 2026 – August 11, 2026
The thesis — published May 13, 2026
Predicted growth
+12%
over the measurement windowTarget price
$1,127.69
the price the thesis aimed forEntry zone
$960.00 – $1,010.00
the fair-value band we waited forPrice at publication
$1,006.87
published May 13, 2026Confidence
70%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly is a fast-growing drug company and new data showing people keep weight off after treatment supports big demand for its obesity medicine. The company posts strong results and leads in its drug areas, but the stock has run up a lot, so timing matters. It looks attractive on price pullbacks, though debt and current valuation reduce near-term upside.
Primary drivers
- New weight-loss data makes Lilly's obesity drug story stronger
- Consistent strong results justify a higher stock price
- Diabetes and obesity drugs create a large growth runway
- High recent gains mean entry should be selective
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.